New Products

Asserachrom® HPIA-IgG for detection of anti-heparin/PF4 IgG antibodies

HIT is a rare but serious prothrombotic complication associated with UFH and LMWH treatments. Diagnosis of HIT is based on clinical (4T’s score) and laboratory criteria. Nevertheless, over-diagnosis and over-treatment are currently the major problem [1]

a clinical HIT is confirmed in only [±10%] of patients with a suspicion of HIT [2].

In 90% of patients investigated for HIT, it is important to rule-out HIT early and :

5B9 Monoclonal Antibody: Fully mimics the effects of human HIT antibodies

5B9 is a monoclonal antibody that fully mimics the effects of human Heparin Induced Thrombocytopenia (HIT) antibodies [1]:

anti-PF4/Heparin IgG antibody with human Fc fragment,
induces heparin- and FcϒRIIA-dependent platelet activation,
specific to the PF4/Heparin complex with very low reactivity against PF4 alone.

5B9 clinical research on HIT functional assays covers the following objectives:

Microvesicles analysis: expand the limits!

Standardized and compliant with international guidelines, CY-QUANT MV-TF Activity is the newborn in the range of microvesicles testing from Stago.

Lupus Anticoagulant - An integrated solution

Stago offers Screening, Mixing and Confirmatory testing solutions for dRVV and APTT pathways and a CE marked automated clinical decision algorithm.

SAME™ by i-SEP®, a revolutionary cell salvage system

SAME ™ by i-SEP® is an innovative autotransfusion system and the only one in the market that retains platelets and platelet activity. The red blood cell yield is comparable to other systems in the market (~90%), but the retention of platelets (upto 81%) is much greater that competitive systems (typically less than 11%).